Controlled Release of Drug Delivery to Reduce the Progression of Alzheimer’s DiseaseName : Afrooz Seyedebrahimi
Affliation : Researcher
University : South Tehran Branch University
Country : Tehran, Iran
Alzheimer's disease (AD) is the most common form of dementia. Studies show that Amyloid-Beta is Crucial Factor in Alzheimer's disease. In AD, the dysregulation of the amyloid-beta (Aβ) level causes the appearance of plaques which contain Aβ depositions. Previous Studies show that there are a whole range of natural and synthetic drugs that with the aim of controlling disease progression with have symptoms of side effects for AD patients. In accordance with Previous Studies, with Traditional drug delivery systems there are no control on place, time and drug release rate. The aim of our study was impact assessment of Controlled release of drug delivery in specific time in AD patients with this novelty that when medicine in dealing with three brain tissues: (healthy brain tissue, AD tissue, another pathogenic tissues) and should Release medicine only for AD tissue. In this research in continuation of the previous research work, Controlled release of drug delivery in time has been done using matlab software. With this simulation, drug delivery system only in dealing with AD tissue, releases the drug. The amount of drug released by controlling the time, place and the rate in dealing with only AD tissue and for three brain tissues has been calculated. The results shown that controlled release of drug delivery at the specific time by an intelligent drug delivery system will be effective in reducing progression of Alzheimer's disease.
Afrooz Seyedebrahimi is a researcher in the South Tehran Branch University, Tehran, Iran. He received his Master degree in Electrical Engineering- Mechatronics. And now I am a researcher in Institute for Cognitive and Brain Sciences, Shahid Beheshti University, Tehran, Iran.